… of 41 patients with advanced gliomas responded to erlotinib, … of tissue from glioblastoma
patients treated with erlotinib or gefitinib … of single-agent erlotinib in patients with first-relapse …

… Furthermore, KRAS mutation status did not predict how patients would respond to erlotinib
in our study, which is in line with the pivotal PA.3 study [17]. The small numbers of patients in …

… (11 [13%] of 84 patients given erlotinib vs none of 82 patients in the chemotherapy group), …
patients on erlotinib had treatment-related severe adverse events compared with 16 patients …

… patients in this study received treatment with erlotinib for a longer duration than patients …
Six out of the total 108 patients included in the erlotinib second-/third-line Japanese studies …

… 3b, multicenter, open-label trial of erlotinib in patients with … and safety of erlotinib monotherapy
in patients with advanced … of erlotinib-treated patients in subpopulations defined by other …

… Registration trials for erlotinib were restricted to patients with … 150 mg dose of erlotinib in
cancer patients with moderate hepatic … erlotinib protein binding in cancer patients with MHI. …

… Patients were stratified by EGFR mutation type, ECOG PS, gender, and country. … , erlotinib
patients could crossover to receive GP and GP patients could crossover to receive erlotinib. All …

… of erlotinib plus bevacizumab with erlotinib alone in patients … patients given bevacizumab
and erlotinib had improved progression-free survival compared with patients given erlotinib …

… 83 patients were randomly assigned to receive erlotinib and 82 to receive gemcitabine plus
carboplatin; 82 in the erlotinib … of erlotinib was 50 mg/day; any patient receiving an erlotinib …

… Patients and Methods … plus erlotinib study (BEVERLY) is a randomized, open-label,
phase III trial investigating first-line erlotinib plus bevacizumab versus erlotinib in patients with …